0.2130SEK-1.62%Mkt Cap: 141.32M SEKP/E: —Last update: 2026-05-13
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40,…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-2.81
PEG—
P/B1.43
P/S271.78
EV/EBITDA-1.69
EV/Revenue270.63
EPS (TTM)-1.33
EPS (Forward)-0.08
Cash Flow & Leverage
FCF Yield-133.74%
FCF Margin-36347.52%
Operating CF-155.99M SEK
CapEx (TTM)1.46M SEK
Net Debt/EBITDA0.01
Net Debt-597.00K SEK
Technical
SMA 500.2099 (+1.5%)
SMA 2001.502 (-85.8%)
Beta1.24
S&P 52W Chg24.23%
Avg Vol (30d)30.25M
Avg Vol (10d)8.03M
Technical Indicators
RSI (14)48.0
MACD-0.0016
MACD Signal0.0019
MACD Hist.-0.0035
BB Upper0.3288 SEK
BB Middle0.2407 SEK
BB Lower0.1527 SEK
BB Width73.13%
ATR (14)0.0323 SEK
Vol Ratio (20d)0.06x
52W Range
0.15701% of range7.210
52W High7.210 SEK
52W Low0.1570 SEK
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin-9990.27%
Oper. Margin-18215.31%
ROE-748.65%
ROA-46.43%
Revenue Growth-69.30%
Earnings Growth—
Balance Sheet
Debt/Equity6.29
Current Ratio1.76
Quick Ratio1.21
Book Value/Sh0.1570 SEK
Cash/Share0.0530 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:1000
Split DateApr 7, 2025
Ownership
Shares Out.628.11M
Float613.86M
Insiders16.45%
Institutions1.93%
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)0.3000 SEK
Target Range0.3000 SEK – 0.3000 SEK
# Analysts1
Company
Market Cap141.32M SEK
Enterprise Value140.73M SEK
Revenue (TTM)520.00K SEK
Gross Profit-60.09M SEK
Net Income (TTM)-51.35M SEK
Revenue/Share0.0030 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees11
Last Price0.2130 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—